NEPH (Nephros) ROCE %: 3.50% (As of Mar. 2026)

What is Nephros ROCE %?

Nephros NEPH -0.61% 63 ROCE % is 3.50% as of Mar. 2026. GuruFocus rates NEPH with a GF Score™ of 63/100 and a GF Value™ of $2.87 (Modestly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nephros's annualized ROCE % for the quarter that ended in Mar. 2026 was 3.50%.

Nephros (NAS:NEPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nephros ROCE % Related Terms

Nephros ROCE % Historical Data

* Premium members only.

The historical data trend for Nephros's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nephros ROCE % Chart

Nephros Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-16.91

-34.27

-16.27

0.93

11.76

Nephros Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															22.74	9.53	12.80	2.29	3.50

63GF Score

Nephros Inc NEPH

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nephros ROCE % Calculation

Nephros's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	1.207	/	( ( (11.21 - 1.562)	+	(13.641 - 2.767) )	/ 2 )
	=	1.207	/	( (9.648	+	10.874)	/ 2 )
	=	1.207	/	10.261
	=	11.76 %

Nephros's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	0.388	/	( ( (13.641 - 2.767)	+	(13.794 - 2.527) )	/ 2 )
	=	0.388	/	( ( 10.874	+	11.267 )	/ 2 )
	=	0.388	/	11.0705
	=	3.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 3.50% mean?

Nephros (NEPH) has a ROCE % of 3.50% as of Mar. 2026.

Is Nephros' ROCE % too high?

Nephros' current ROCE % is 3.50%. The Medical Devices & Instruments industry median ROCE % is 2.23. Nephros' value of 3.50% is 57% above this industry median. Overall, Nephros has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Nephros' ROCE % compare to MLSS and HBIO?

Nephros' ROCE % of 3.50% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Nephros' value of 3.50% is 57% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nephros's current ROCE % of 3.50% is 57% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephros's current ROCE % is 3.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nephros stock overvalued right now?

Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.87, compared to a current price of $3.30 — trading 15% above its estimated fair value. The current ROCE % is 3.50% and 57% above the Medical Devices & Instruments industry median of 2.23. Nephros' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Nephros (NEPH), the current ROCE % is 3.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nephros (NEPH) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of $3.30 is trading 15% above its estimated GF Value™ of $2.87. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for NEPH:

ROCE %: 3.50%
GF Value™: $2.87 vs. price of $3.30 (15% above fair value)
GF Score™: 63/100 with 5 warning signs
Industry Position: 57% above the Medical Devices & Instruments median

No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nephros Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies MLSS HBIO FEMY RVP POCI DXR ZJYL UEEC BNGO RGNT ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges NPJP:Germany

Address 380 Lackawanna Place, South Orange, NJ, USA, 07079

Website https://www.nephros.com

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

63GF Score

Get the complete analysis for NEPH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.30

Price

$2.87

GF Value

View NEPH Analysis

See ROCE % data for all stocks →